Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 120,000 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total value of $1,504,800.00. Following the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Natera, Inc. (NASDAQ:NTRA) traded up 2.90% on Thursday, reaching $13.15. The company’s stock had a trading volume of 225,302 shares. The company’s market capitalization is $699.88 million. The firm’s 50 day moving average price is $10.39 and its 200-day moving average price is $9.87. Natera, Inc. has a 1-year low of $7.35 and a 1-year high of $13.25.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.52). The business had revenue of $53.60 million for the quarter, compared to the consensus estimate of $50.57 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.46) EPS. Equities analysts forecast that Natera, Inc. will post ($2.03) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Natera, Inc. (NTRA) Insider Jonathan Sheena Sells 120,000 Shares” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/07/natera-inc-ntra-insider-jonathan-sheena-sells-120000-shares.html.

Several equities research analysts recently commented on the company. Cowen and Company reaffirmed a “buy” rating and set a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. Zacks Investment Research raised Natera from a “sell” rating to a “buy” rating and set a $9.25 price objective on the stock in a research report on Thursday, August 10th. ValuEngine raised Natera from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 10th. BidaskClub raised Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Morgan Stanley dropped their price objective on Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $14.45.

A number of institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA grew its stake in Natera by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after purchasing an additional 194 shares during the last quarter. Wells Fargo & Company MN grew its stake in Natera by 2.8% during the 2nd quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 491 shares during the last quarter. Principal Financial Group Inc. grew its stake in Natera by 0.6% during the 1st quarter. Principal Financial Group Inc. now owns 111,278 shares of the medical research company’s stock valued at $987,000 after purchasing an additional 688 shares during the last quarter. American International Group Inc. grew its stake in Natera by 7.1% during the 1st quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 1,068 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in Natera by 5.6% during the 1st quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock valued at $236,000 after purchasing an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 59.79% of the company’s stock.

Natera Company Profile

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.